MEK drives cyclin D1 hyperelevation during geroconversion
about
Genomic diversity of colorectal cancer: Changing landscape and emerging targetsThe other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axisSmall molecule compounds that induce cellular senescenceBRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implicationsRapamycin induces pluripotent genes associated with avoidance of replicative senescenceContact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence programNuclear accumulation of cyclin D1 following long-term fractionated exposures to low-dose ionizing radiation in normal human diploid cells.Cellular senescence and protein degradation: breaking down cancerIdentification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumorsSulfatase 1 (hSulf-1) reverses basic fibroblast growth factor-stimulated signaling and inhibits growth of hepatocellular carcinoma in animal modelWI-38 senescence is associated with global and site-specific hypomethylation.Growth hormone action predicts age-related white adipose tissue dysfunction and senescent cell burden in mice.CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasisTOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.Selective anti-cancer agents as anti-aging drugsInduced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell.Gerosuppression in confluent cells.Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat dietTumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.Fasting levels of hepatic p-S6 are increased in old miceDifferent effects of ZO-1, ZO-2 and ZO-3 silencing on kidney collecting duct principal cell proliferation and adhesion.The cyclin D1-CDK4 oncogenic interactome enables identification of potential novel oncogenes and clinical prognosisInhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.Rejuvenating immunity: "anti-aging drug today" eight years later.Koschei the immortal and anti-aging drugsRapamycin inhibits Erk1/2-mediated neuronal apoptosis caused by cadmium.Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).M(o)TOR of aging: MTOR as a universal molecular hypothalamusCDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.S6K in geroconversion.Aging is not programmed: genetic pseudo-program is a shadow of developmental growth.Effects of U0126 and MK2206 on cell growth and re-growth of endometriotic stromal cells grown on substrates of varying stiffnessMulti-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells.Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosis.TRAF6 promotes TGFβ-induced invasion and cell-cycle regulation via Lys63-linked polyubiquitination of Lys178 in TGFβ type I receptor.Interaction between ROS dependent DNA damage, mitochondria and p38 MAPK underlies senescence of human adult stem cells.M(o)TOR of pseudo-hypoxic state in aging: rapamycin to the rescue.Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.
P2860
Q26739052-8EB37BF8-6DDC-4DF0-93D3-96F951B9987EQ26865888-3F4D30EB-3AC4-4814-AFB2-FD5AA0109E6DQ28068732-0DEE38C5-849D-426B-8F31-78486AC921A6Q28543370-F9367F3A-4045-444A-A396-5CBA4BB8324BQ28572137-59A01F57-1188-470B-BBB2-54C2EB4664D1Q28972583-EBB56839-A794-4472-A674-2636E59DE913Q33728366-B344166E-FC2F-436F-BC54-021586BC35A2Q33953067-D5239C06-424E-4546-A63A-89A172933545Q34100865-F126E16D-4765-430C-A5A1-A9720BD86D1EQ34104125-8BD6049D-0457-4EF6-82DA-9CDBA1D6BFA4Q34128610-F12D33C8-3777-4512-867A-A8B48AF07B8BQ34128617-F240225E-FA0B-4944-8442-65E88701FD9AQ34227791-4DCB6BD0-5042-48D3-A37D-13E7E9B5DA98Q34334385-D7520243-3D6B-4677-A802-A4087AF26620Q34391710-DB782726-3906-4386-9E3F-3AAAACCB0ACDQ34392470-C6B7BD7E-4733-420E-B417-603D5F3989B8Q34483726-264C7F6C-152C-4B18-B319-D37D2731F81AQ34982499-92D5D9AD-821D-43A5-B67E-0A816D11BE48Q35080619-F62F67ED-E43F-4947-A04E-16D98E95613FQ35149607-6DB0684C-1D6D-4694-AA9C-4ED6E0E6203EQ36182265-0D299FBD-6C23-430E-B041-5A0EA69B7FBEQ36182415-7DCE5C6B-727A-450A-B8AA-11A25F5330C8Q36186374-026505D5-96E6-4581-BAA9-47353FE8B085Q36187896-25E879E8-BE88-4D2D-A770-4B18820B1957Q36189481-AE5635F2-4A45-4D13-BAA7-A9B3036D8FB6Q36260537-4CDEDF3D-54D7-4892-86D4-0E4FCD99889AQ36292001-FF086C7F-7431-4C17-9622-32CA265903DEQ36356365-1BD1EDF2-0DD2-4DF3-896D-4C577539BC0DQ36414149-6C85BB0F-502B-4AC0-B927-57740F323166Q37152775-D10481D1-5C57-4078-8173-B283EEAC5513Q37420058-012D2406-BB24-4CC0-8C48-F7D5FBE9FDAAQ37452951-41E7B227-6760-4F53-8D9D-2D5008EC6781Q37525814-F71B2957-3A50-4E46-B1FE-23FFC088457AQ37652650-47394E97-9BC0-4353-AE6C-8863E454979FQ37706959-49598A56-7BCA-4C97-906C-050DF8212DCFQ38826343-668ADDDA-1CED-4EED-B0EF-826A995EFF40Q38916414-8B055B99-B32C-464B-8AD0-CCF3127B504CQ38984158-134C7390-A955-4776-BDBB-EBA818D4FE86Q39027265-F3F32A11-74E4-41A5-9229-2BAD191D8151Q40789497-E76588FD-C98F-4C0F-8C75-21E59C16B9A3
P2860
MEK drives cyclin D1 hyperelevation during geroconversion
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
MEK drives cyclin D1 hyperelevation during geroconversion
@en
MEK drives cyclin D1 hyperelevation during geroconversion.
@nl
type
label
MEK drives cyclin D1 hyperelevation during geroconversion
@en
MEK drives cyclin D1 hyperelevation during geroconversion.
@nl
prefLabel
MEK drives cyclin D1 hyperelevation during geroconversion
@en
MEK drives cyclin D1 hyperelevation during geroconversion.
@nl
P2093
P2860
P356
P1476
MEK drives cyclin D1 hyperelevation during geroconversion
@en
P2093
M V Blagosklonny
O V Leontieva
Z N Demidenko
P2860
P2888
P304
P356
10.1038/CDD.2013.86
P577
2013-07-12T00:00:00Z